Roche
NEWS
Avista Therapeutics inked a partnership deal with Swiss pharma giant Roche to develop AAV gene therapy vectors for eye diseases.
Roche had a good week, sharing positive data from Genentech’s study on Vabysmo for age-related macular degeneration and its breast cancer combination therapy, Perjeta.
Early data from Amgen’s ongoing trial on Lumakras for non-small cell lung cancer hinted at positive results from what could be a transformative combination of drugs versus cancer.
uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company’s president of R&D, Dr. Ricardo Dolmetsch.
The experimental drug, being developed to treat immunoglobulin A nephropathy, is IONIS-FB-L Rx, which hit the mark in a Phase II study showing a change in urinary protein after 29 weeks of treatment.
Sanofi announced positive data for its therapeutic, fitusiran, for treating patients with hemophilia A and B, as well as efanesoctocog alfa therapy for treating hemophilia A.
Sarepta Therapeutics and its partner, Roche, presented promising functional data from several trials of its gene therapy for Duchenne muscular dystrophy.
Eisai and Biogen’s BLA for lecanemab for Alzheimer’s disease received FDA Priority Review with a target action date of January 6, 2023, while Roche’s lymphoma drug scored the same designation.
The Roche Accelerator is designed to help companies bridge the gap between idea and proof-of-concept. It is one of several incubators recently founded by Western companies.
JOBS
IN THE PRESS